Report From the 2024 International Dermatology Outcome Measures (IDEOM) Annual Meeting
December 2025 | Volume 24 | Issue 12 | 1215 | Copyright © December 2025
Published online November 28, 2025
Sarah Romanelli BSa*, Gretchen D. Ball BSa*, Arianna J. Zhang BAb, Christina Asare BSc, Audrey Hao BSd, Hassan Hamade MDa, Grace M. Hren BSa,e, Yvonne Nong MDf, John S Barbieri MD MBAb, Saakshi Khattri MD FACR FAANa, Tarannum Jaleel MDg, Winston W. Liu MD PhDh,i, Brian Kim MD MTRa, Michi Shinohara MDj, Cecilia Larocca MDb, Daniel Butler MDk, Daniel Siegel MD MS FAAD FACMSl,m, Nanette Silverberg MDa, Silvia F. Barrio n, Robin Christensen BSc MSc PhDo,p,q, Athena Ehlert r, John Latella r, Vibeke Strand MDs, April W. Armstrong MD MPHf, Lourdes Perez-Chada MD MMScb, Joseph F. Merola MD MMSct**, Alice B. Gottlieb MD PhDa**
aDepartment of Dermatology, Icahn School of Medicine at Mount Sinai, NY, NY
bDepartment of Dermatology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA
cGeorgetown University School of Medicine, Washington, DC
dKeck School of Medicine, University of Southern California,
Los Angeles, CA
eDepartment of Dermatology, Stony Brook University, NY, NY
fDivision of Dermatology, Department of Medicine, David Geffen School of Medicine at the University of California, Los Angeles, CA gDepartment of Dermatology, Duke University, Durham, NC
hDepartment of Dermatology, Stanford University
iSchool of Medicine, Duke University, Durham, NC
jUniversity of Washington Department of Dermatology and Fred Hutchinson Cancer Center, Seattle, WA
kUniversity of Arizona College of Medicine – Tucson, Tucson, AZ
lDepartment of Dermatology, SUNY Downstate Medical Center, Brooklyn, NY
mDepartment of Dermatology, VA New York Harbor Healthcare System, Brooklyn, NY
nInternational Federation of Psoriasis Associations, Stockholm, Sweden
oSection for Biostatistics and Evidence-Based Research, the Parker Institute, Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark pResearch Unit of Rheumatology, Department of Clinical Research, University of Southern Denmark, Odense University Hospital, Denmark
qCochrane Denmark & Centre for Evidence-Based Medicine Odense (CEBMO), Department of Clinical Research, University of Southern Denmark, Denmark
rInternational Dermatology Outcome Measures, Roseville, CA
sDivision of Immunology/Rheumatology, Stanford University, Palo Alto, CA
tDepartment of Dermatology, UT Southwestern Medical Center, Dallas, TX
Abstract
Background: International Dermatology Outcome Measures (IDEOM) is a nonprofit organization committed to advancing the development and accessibility of evidence-based, consensus-driven outcome measures in dermatology. This mission is supported by a diverse group of stakeholders who collaborate to improve the research and treatment of dermatologic disease.
Summary: The 2024 IDEOM Annual Meeting was held on April 5-6, 2024. During the event, work groups in psoriatic disease, hidradenitis suppurativa, geriatric dermatology, connective tissue disease, vitiligo, itch, actinic keratosis, acne, and cutaneous T-cell lymphoma discussed research progress and conducted breakout sessions. This report summarizes each workgroup’s updates.
Key Messages: This report outlines the key research advancements made by each IDEOM workgroup at the 2024 IDEOM Annual Meeting.
INTRODUCTION
International Dermatology Outcome Measures (IDEOM) is a nonprofit organization dedicated to developing validated patient-reported outcome measures PROMs (patient-reported outcome measures) for dermatologic research and clinical practice. IDEOM comprises a diverse group of stakeholders, including patients, physicians, government agencies, industry professionals, nonprofits, and researchers. IDEOM's PROMs are freely available.
Annually, IDEOM stakeholders convene in work groups to assess progress, share study results, and plan future research. Work groups focus on psoriatic disease, hidradenitis suppurativa (HS), geriatric dermatology, connective tissue disease (CTD), vitiligo, itch, actinic keratosis (AK), acne, and cutaneous T-cell lymphoma (CTCL). This report highlights the advancements presented by the work groups during the 2024 IDEOM Annual Meeting.
